SCHEMBL7550236

SCHEMBL7550236

CC1CN(C(=O)CCl)c2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.69
DRD2 P14416 1/20 0.57
DRD4 P21917 1/20 0.57
CASP3 P42574 1/20 0.46
CASP2 P42575 1/20 0.46
NPC1 O15118 2/20 0.45
MITF O75030 2/20 0.45
RAB9A P51151 2/20 0.45
AKT1 P31749 4/20 0.45
PIK3CD O00329 2/20 0.45
PIK3CB P42338 2/20 0.45
PIK3CG P48736 2/20 0.45
CYP3A4 P08684 1/20 0.45
PIK3CA P42336 1/20 0.45
KMT2A Q03164 3/20 0.44
TP53 P04637 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11550105 0.83 NOTUM (0.48) NOTUMDRD2DRD4CASP3CASP2
SCHEMBL24377961 0.83 NOTUM (0.48) NOTUMDRD2DRD4CASP3CASP2
SCHEMBL14294095 0.81 NOTUM (1.00) NOTUMDRD2DRD4AKT1PIK3CD
SCHEMBL27852096 0.81 NOTUM (0.75) NOTUMDRD2DRD4AKT1PIK3CD
SCHEMBL11554895 0.79 NOTUM (0.43) NOTUMDRD2DRD4CASP3CASP2
SCHEMBL24377959 0.78 CASP3 (0.44) NOTUMDRD2DRD4CASP3CASP2
SCHEMBL11551165 0.77 DRD2 (0.48) NOTUMDRD2DRD4CASP3CASP2
SCHEMBL8208943 0.76 DRD2 (0.65) NOTUMDRD2DRD4AKT1PIK3CD
SCHEMBL26938740 0.75 SIRT1 (0.51) NOTUMCASP3CASP2NPC1RAB9A
SCHEMBL26938724 0.75 SIRT1 (0.51) NOTUMCASP3CASP2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020128274-A1 Benzylpiperazinyl-indolinylethanones NEUROGEN CORPORATION. 2002-09-12 US disclosed
US-6355644-B1 NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER NEUROGEN CORPORATION 2002-03-12 US disclosed
WO-2000076967-A1 BENZYLPIPERAZINYL-INDOLINYLETHANONES NEUROGEN CORPORATION (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128274-A1 Benzylpiperazinyl-indolinylethanones GABRP, GABBR1, GABARAP NOTUM 4023/4885DRD2 30/4885DRD4 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.